GERON CORP

Geron Corporation granted a stock option to purchase 1,700,000 shares of its common stock to Chinmaya Rath, the new Chief Business Officer. This award, with an exercise price of $1.42 per share, serves as an inducement for his employment and vests over four years. The grant was approved by the Compensation Committee in accordance with Nasdaq rules.

Geron Corporation announced the appointment of Chinmaya Rath as its new Chief Business Officer. Mr. Rath brings over 25 years of extensive U.S. and global biopharma leadership experience, including significant roles at Novartis, Cellworks, and GlycoMimetics. His appointment is expected to enhance the company's strategic insights and execution, focusing on maximizing the global value of RYTELO and evaluating opportunistic innovation to build a leading hematology company.

Geron Corporation's stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing the number of shares available for issuance by 4,500,000. This decision was made at the 2026 Annual Meeting, where stockholders also re-elected three Class III directors for a three-year term. Additionally, they approved the non-binding advisory vote on executive compensation and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Geron Corporation reported that it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees, effective May 15, 2026. These options, with an exercise price of $1.29 per share, were provided as an inducement for their acceptance of employment. The awards have a ten-year term and vest over four years, subject to continued employment.

Geron Corporation announced positive real-world evidence for RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS), with data to be presented at the European Hematology Association (EHA) 2026 Congress. The investigator-sponsored study at Moffitt Cancer Center demonstrated safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population. The study reported a 37.5% red blood cell transfusion independence rate lasting at least eight weeks in heavily pretreated LR-MDS patients. Geron will also present additional data on its myelofibrosis and AML clinical programs at EHA 2026 and ASCO 2026.

Geron Corporation reported a significant improvement in its first quarter 2026 financial results, with net loss narrowing to $3.64 million, a substantial reduction from $19.84 million in the prior year. Total revenues increased by 31% to $51.84 million, primarily driven by strong product revenue from RYTELO. The company also amended its Pharmakon Loan Agreement, extending the availability of Tranche B and C loans and the make-whole premium date. Ongoing legal proceedings related to securities class action and derivative lawsuits continue.

Geron Corporation reported Q1 2026 RYTELO net product revenue of $51.8 million, an 8% increase from Q4 2025, and a net loss of $3.6 million, significantly reduced from $19.8 million in Q1 2025. The company reiterated its 2026 RYTELO net product revenue guidance of $220 million to $240 million and total operating expenses of $230 million to $240 million. Geron also strengthened its leadership team with new appointments and ended the quarter with $341 million in cash and marketable securities.

Geron Corporation announced it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time on the same day. Investors can access the press release and webcast details on the Investors and Media section of Geron's website.

Geron Corporation granted stock options for an aggregate of 855,000 shares of common stock to nine newly hired employees. These grants, effective April 17, 2026, serve as an inducement for their employment. The options have an exercise price of $1.68 per share, a ten-year term, and vest over four years, with an initial 12.5% vesting after six months.

Geron Corporation granted an inducement equity award of a stock option to purchase 2,500,000 shares to Timothy Williams, its new Executive Vice President, Chief Legal Officer and Corporate Secretary. The option, granted on April 13, 2026, has an exercise price of $1.73 per share and vests over four years, aiming to attract and retain key executive talent.